Idexx has announced the UK and Ireland launch of the Catalyst SDMA Test, a kidney function test for cats and dogs which can be added to the routine chemistry panel of the company's Catalyst One and Catalyst Dx chemistry analyzers and performed by practices in-house, with results available in minutes.Idexx has announced the UK and Ireland launch of the Catalyst SDMA Test, a kidney function test for cats and dogs which can be added to the routine chemistry panel of the company's Catalyst One and Catalyst Dx chemistry analyzers and performed by practices in-house, with results available in minutes.

Idexx says the new test is proven to identify kidney disease earlier than creatinine1–3, enabling veterinary surgeons to intervene earlier and have a greater impact on patients' health outcomes and quality of life. 

The Catalyst SDMA Test was first launched at the company's reference laboratories in 2015, since when Idexx says it has run more than 14 million SDMA patient tests, creating the world's largest database on kidney disease in dogs and cats.

The test was then launched to veterinary practices in the USA and Canada last December, where Idexx says it has now been used by thousands of practices.

Jonathan Ayers, Chairman and Chief Executive Officer of Idexx Laboratories said: "We've seen great enthusiasm for the ability to run SDMA as part of the routine chemistry panel at the point of care, and the North American launch has exceeded our expectations.

"The Idexx SDMA Test represents one of the most significant diagnostic innovations in veterinary medicine in the last 30 years. We're thrilled to bring this essential element of the chemistry panel to our point of care Idexx VetLab suite, allowing veterinarians to utilize the benefits of SDMA immediately during the pet's appointment."

Idexx has also signed an agreement to collaborate with Yale University to explore the test's applications in human health. As a result of the partnership, the SDMA Test has been validated for accuracy in measuring SDMA in human blood samples and the results presented at the 2017 annual meeting of the American Society of Nephrology last November by Yale and IDEXX researchers. 

Jonathan added: "SDMA has tremendous potential benefit in human applications as well. And with the Idexx test technology now validated to be able to run on commercial chemistry systems that routinely produce chemistry results in human reference laboratories, we have greater reason to explore the clinical value of this incredible biomarker in human applications. We are excited and grateful for our partnership with Yale University."

Idexx says SDMA is now the subject of more than 30 ongoing research collaborations and has been incorporated into the veterinary profession's International Renal Interest Society (IRIS) kidney disease staging guidelines. 

For more information about the IDEXX Catalyst SDMA Test, visit www.idexx.eu/sdma.

References

  1. Nabity MB, Lees GE, Boggess M, Yerramilli M, Obare E, Yerramilli M, Rakitin A, Aguiar J, Relford R. Symmetric dimethylarginine assay validation, stability, and evaluation as a marker for early detection of chronic kidney disease in dogs. J Vet Intern Med. 2015;29(4):1036–1044. 
  2. Hall JA, Yerramilli M, Obare E, Yerramilli M, Jewell DE. Comparison of serum concentrations of symmetric dimethylarginine and creatinine as kidney function biomarkers in cats with chronic kidney disease. J Vet Intern Med. 2014;28(6):1676–1683. 
  3. Hall JA, Yerramilli M, Obare E, Yerramilli M, Almes K, Jewell DE. Serum concentrations of symmetric dimethylarginine and creatinine in dogs with naturally occurring chronic kidney disease. J Vet Intern Med.2016;30(3):794–802.

PS: Whilst you're here, take a moment to see our latest job opportunities for vet nurses.